US 12,403,195 B2
Sensitizing cells to proton radiation
Adam J. Harvey, Minneapolis, MN (US); Michael D. Kaytor, Maplewood, MN (US); Keith Cengel, Bala Cynwyd, PA (US); and Eric Stanton Diffenderfer, Wayne, PA (US)
Assigned to Humanetics Corporation, Excelsior, MN (US); and Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by Humanetics Corporation, Minneapolis, MN (US); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Aug. 31, 2023, as Appl. No. 18/240,816.
Application 18/240,816 is a continuation of application No. 17/486,499, filed on Sep. 27, 2021, granted, now 11,779,644.
Application 17/486,499 is a continuation of application No. 16/145,787, filed on Sep. 28, 2018, granted, now 11,129,894, issued on Sep. 28, 2021.
Claims priority of provisional application 62/565,970, filed on Sep. 29, 2017.
Prior Publication US 2024/0173412 A1, May 30, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 41/00 (2020.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 9/51 (2006.01); A61K 31/353 (2006.01); A61K 47/32 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01)
CPC A61K 41/0038 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 9/51 (2013.01); A61K 31/353 (2013.01); A61K 47/32 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); A61N 2005/1087 (2013.01); A61N 2005/1098 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for sensitizing tumor cells to high linear energy transfer (LET) proton radiation, the method consisting essentially of:
contacting the tumor cells with a composition consisting essentially of one or more pharmaceutically acceptable carriers and nanoparticulate genistein, wherein the tumor cells are contacted with the nanoparticulate genistein at a concentration of 5 uM (micromolar), and
contacting the tumor cells with the high LET proton radiation, wherein the genistein is effective to sensitize the tumor cells to the proton radiation, in a manner that the tumor cells are reduced in number and therapeutically effectively treated with a dose of the high LET proton radiotherapy that is at least 10% less than a dose of high LET proton radiotherapy that would need to be administered to corresponding number of tumor cells not treated with the genistein composition.